Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Assets (2016 - 2025)

Historic Assets for Angiodynamics (ANGO) over the last 17 years, with Q4 2025 value amounting to $269.7 million.

  • Angiodynamics' Assets fell 751.68% to $269.7 million in Q4 2025 from the same period last year, while for Nov 2025 it was $269.7 million, marking a year-over-year decrease of 751.68%. This contributed to the annual value of $280.1 million for FY2025, which is 1181.32% down from last year.
  • Per Angiodynamics' latest filing, its Assets stood at $269.7 million for Q4 2025, which was down 751.68% from $265.6 million recorded in Q3 2025.
  • In the past 5 years, Angiodynamics' Assets ranged from a high of $582.2 million in Q1 2021 and a low of $265.6 million during Q3 2025
  • For the 5-year period, Angiodynamics' Assets averaged around $443.2 million, with its median value being $516.1 million (2023).
  • Per our database at Business Quant, Angiodynamics' Assets skyrocketed by 74.07% in 2022 and then crashed by 4163.6% in 2024.
  • Quarter analysis of 5 years shows Angiodynamics' Assets stood at $554.1 million in 2021, then rose by 0.74% to $558.2 million in 2022, then fell by 10.5% to $499.6 million in 2023, then crashed by 41.64% to $291.6 million in 2024, then dropped by 7.52% to $269.7 million in 2025.
  • Its last three reported values are $269.7 million in Q4 2025, $265.6 million for Q3 2025, and $280.1 million during Q2 2025.